These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 8846658

  • 1. Fluoride therapy of type I osteoporosis.
    Devogelaer JP, Nagant de Deuxchaisnes C.
    Clin Rheumatol; 1995 Sep; 14 Suppl 3():26-31. PubMed ID: 8846658
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallack RW, Dhaliwal SS, Stuckey BG, Drury P, Jones CE, Faulkner DL, Kent GN, Bhagat CI, Nicholson GC, Jamrozik K.
    Osteoporos Int; 2002 Sep; 13(2):158-70. PubMed ID: 11908491
    [Abstract] [Full Text] [Related]

  • 3. Effects of different regimens of sodium fluoride treatment for osteoporosis on the structure, remodeling and mineralization of bone.
    Balena R, Kleerekoper M, Foldes JA, Shih MS, Rao DS, Schober HC, Parfitt AM.
    Osteoporos Int; 1998 Sep; 8(5):428-35. PubMed ID: 9850350
    [Abstract] [Full Text] [Related]

  • 4. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
    Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ.
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S143-7. PubMed ID: 2339624
    [Abstract] [Full Text] [Related]

  • 5. Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.
    Pak CY, Adams-Huet B, Sakhaee K, Bell NH, Licata A, Johnston C, Rubin B, Bonnick S, Piziak V, Graham H, Ballard J, Berger R, Fears W, Breslau N, Rubin C.
    J Bone Miner Res; 1996 Feb; 11(2):160-8. PubMed ID: 8822339
    [Abstract] [Full Text] [Related]

  • 6. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.
    Nagant de Deuxchaisnes C, Devogelaer JP, Depresseux G, Malghem J, Maldague B.
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S5-26. PubMed ID: 2187327
    [Abstract] [Full Text] [Related]

  • 7. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C.
    Ann Intern Med; 1998 Jul 01; 129(1):1-8. PubMed ID: 9652994
    [Abstract] [Full Text] [Related]

  • 8. Sodium fluoride therapy of postmenopausal osteoporosis.
    Kleerekoper M, Mendlovic DB.
    Endocr Rev; 1993 Jun 01; 14(3):312-23. PubMed ID: 8319597
    [Abstract] [Full Text] [Related]

  • 9. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD, Kipshoven C, Cöster A, Umbach R.
    Osteoporos Int; 1999 Jun 01; 9(2):171-8. PubMed ID: 10367046
    [Abstract] [Full Text] [Related]

  • 10. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial.
    Pak CY, Sakhaee K, Piziak V, Peterson RD, Breslau NA, Boyd P, Poindexter JR, Herzog J, Heard-Sakhaee A, Haynes S, Adams-Huet B, Reisch JS.
    Ann Intern Med; 1994 Apr 15; 120(8):625-32. PubMed ID: 8135445
    [Abstract] [Full Text] [Related]

  • 11. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
    Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X.
    Osteoporos Int; 1998 Apr 15; 8(1):4-12. PubMed ID: 9692071
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis.
    Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM.
    Osteoporos Int; 1991 Jun 15; 1(3):155-61. PubMed ID: 1790403
    [Abstract] [Full Text] [Related]

  • 13. Bioavailability of fluoride in postmenopausal women: comparative study between sodium fluoride and disodium monofluorophosphate-calcium carbonate.
    Lioté F, Bardin C, Liou A, Brouard A, Terrier JL, Kuntz D.
    Calcif Tissue Int; 1992 Mar 15; 50(3):209-13. PubMed ID: 1617494
    [Abstract] [Full Text] [Related]

  • 14. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis.
    Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS.
    Arch Intern Med; 2001 Oct 22; 161(19):2325-33. PubMed ID: 11606148
    [Abstract] [Full Text] [Related]

  • 15. Effect of intermittent therapy with a slow-release fluoride preparation.
    Pak CY, Sakhaee K, Zerwekh JE.
    J Bone Miner Res; 1990 Mar 22; 5 Suppl 1():S149-55. PubMed ID: 2339625
    [Abstract] [Full Text] [Related]

  • 16. Comparison of serum fluoride levels after administration of monofluorophosphate-calcium carbonate or sodium fluoride: differences in peak serum concentrations.
    Erlacher L, Teufelsbauer H, Bernecker P, Pietschmann P, Weissel M.
    Clin Investig; 1994 Dec 22; 72(12):1082-5. PubMed ID: 7711420
    [Abstract] [Full Text] [Related]

  • 17. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
    Murray TM, Ste-Marie LG.
    CMAJ; 1996 Oct 01; 155(7):949-54. PubMed ID: 8837545
    [Abstract] [Full Text] [Related]

  • 18. [The treatment of vertebral osteoporosis. Use of sodium fluoride and sodium monofluorophosphate in combination with calcium].
    Meunier PJ.
    Fortschr Med; 1990 Jan 15; 108(1):45-8. PubMed ID: 2179080
    [Abstract] [Full Text] [Related]

  • 19. Sodium fluoride treatment is a major protector against vertebral and nonvertebral fractures when compared with other common treatments of osteoporosis: a longitudinal, observational study.
    Farrerons J, Rodríguez de la Serna A, Guañabens N, Armadans L, López-Navidad A, Yoldi B, Renau A, Vaqué J.
    Calcif Tissue Int; 1997 Mar 15; 60(3):250-4. PubMed ID: 9069161
    [Abstract] [Full Text] [Related]

  • 20. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.
    Osteoporos Int; 2003 Sep 15; 14(9):741-9. PubMed ID: 12827224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.